Benchmark lowered the firm's price target on Milestone Scientific to $1 from $1.25 and keeps a Speculative Buy rating on the shares. Sales traction for the Medical business has proven to be elusive, so the firm is lowering its forward revenue estimates, noting that its 2030 revenue estimate of $22M is discounted to the end of 2026 at 8.2% to arrive at its lowered price target.
